PT-141 (Bremelanotide) Effect on CMP (Comprehensive Metabolic Panel)
HealthRX.com
The label does not list CMP changes among its adverse reactions
Key numbers
- 40 timesAcute hepatitis case: transaminase level compared with the upper limit of normalSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 2-foldDrug exposure (AUC) in severe kidney impairment, compared with normal kidney functionSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 40.0%Nausea in Vyleesi patients in the label (placebo: 1.3%)Source: dailymed.nlm.nih.gov, as cited Nov 7, 2026
At a glance
- Drug / bremelanotide (Vyleesi), 1.75 mg subcutaneous autoinjector, used as needed
- Liver enzymes / one acute hepatitis case in the open-label extension; liver tests normal 4 months after stopping [1]
- Renal impairment / AUC about 1.5-fold higher in moderate and 2-fold higher in severe impairment [1]
- Hepatic impairment / AUC about 1.2-fold higher in mild and 1.7-fold higher in moderate impairment [1]
- Electrolytes, glucose, calcium, albumin / not among the adverse reactions in the label [1]
- Creatine phosphokinase / increased in under 2% of users, more often than placebo; not a CMP test [1]
- Pre-treatment checks in the label / cardiovascular risk and blood pressure control [1]
Does Bremelanotide Change CMP Results?
The label's safety data come from two identical 24-week double-blind trials, with 1,247 women in the safety population (627 on Vyleesi, 620 on placebo) [1]. Across the clinical development program, the label states there was no imbalance between treatment groups in serum transaminase outliers or other signals for hepatotoxicity [1]. None of the adverse reactions the label lists, common or less common, is a change in a CMP test [1].
The label's Warnings and Precautions cover three things: a transient rise in blood pressure with a fall in heart rate, focal hyperpigmentation, and nausea [1]. None of them is a laboratory monitoring instruction. The label says to consider the patient's cardiovascular risk and ensure blood pressure is well controlled before starting, and to reconsider both periodically during treatment [1].
Questions worth asking
The One Liver Case in the Label
Under less common adverse reactions, the label describes a single case of acute hepatitis in the open-label, uncontrolled extension phase of one study. The patient had received 10 doses of Vyleesi over one year and presented with serum transaminases above 40 times the upper limit of normal, total bilirubin 6 times the upper limit of normal and alkaline phosphatase less than 2 times the upper limit of normal [1]. Liver tests returned to normal four months after the study drug was stopped. Because another cause was not identified, the label says the role of Vyleesi could not definitively be excluded [1].
A single case in an uncontrolled extension, with no placebo comparator, is a different kind of finding from a rate.
Liver impairment changes how much drug is in the body rather than describing a lab effect: AUC is about 1.2-fold higher in mild and 1.7-fold higher in moderate hepatic impairment [1].
Kidney Markers: BUN, Creatinine, eGFR
The label does not report a change in creatinine, BUN or eGFR with Vyleesi. What it quantifies for the kidneys is drug exposure: AUC is about 1.5-fold higher in moderate renal impairment and 2-fold higher in severe renal impairment [1]. Bremelanotide is broken down by hydrolysis of amide bonds, and 64.8% of a radiolabeled dose is recovered in urine and 22.8% in feces [1].
Electrolytes, Glucose, Calcium and Albumin
The label's list of less common reactions, each occurring in fewer than 2% of Vyleesi-treated patients and more often than on placebo, runs: upper abdominal pain, diarrhea, myalgia, arthralgia, pain, restless leg syndrome, rhinorrhea, increased creatine phosphokinase, increased blood pressure, pain in extremity and focal skin hyperpigmentation [1]. Sodium, potassium, chloride, bicarbonate, glucose, calcium, total protein and albumin do not appear among the label's adverse reactions [1].
Nausea was reported by 40.0% of Vyleesi patients versus 1.3% on placebo, and vomiting by 4.8% versus 0.2% [1]. Nausea was highest after the first dose (21% of patients) and fell to about 3% with later doses [1].
Increased Creatine Phosphokinase
Increased creatine phosphokinase appears among the less common adverse reactions, in fewer than 2% of Vyleesi-treated patients and more often than with placebo [1]. Creatine phosphokinase is a muscle enzyme. It is not one of the tests on a standard CMP.
Blood Pressure Is What the Label Tracks
The label reports maximal increases of 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after a dose, with heart rate reduced by up to 5 beats per minute and values usually back to baseline within 12 hours [1]. Those are maximal figures. In an open-label ambulatory study of 127 premenopausal women dosed once daily for 8 days, mean daytime blood pressure rose 1.9 mmHg systolic (95% CI 1.0 to 2.7) and 1.7 mmHg diastolic (95% CI 0.9 to 2.4), with a mean heart rate fall of 0.5 beats per minute [1]. Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease [1].
Vyleesi, PT-141 and What the Label Covers
These findings come from the Vyleesi label, the FDA-approved bremelanotide product [1][2]. Compounded or research-use PT-141 products are not Vyleesi and are not FDA-approved drugs; compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing, so these findings do not describe those products [3]. HealthRX.com offers PT-141 by prescription.
Check what you know
Question 1 of 5
Score: 0 right, 0 of 5 answered
Frequently asked questions
Does PT-141 (bremelanotide) raise liver enzymes?
Does bremelanotide affect kidney function or creatinine?
Do I need a CMP before starting Vyleesi?
Does PT-141 change electrolytes or blood sugar?
Is creatine phosphokinase part of a CMP?
Does kidney or liver impairment change bremelanotide exposure?
References
Show all 3 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- U.S. Food and Drug Administration.
- Official web page.